Tuesday, May 18, 2010


Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors

Oramed Pharmaceuticals Inc. (OTCBB:ORMP.OB.ob - News) announced that Dr. Michael Berelowitz, MD, joins Oramed Pharmaceuticals' Board of Directors. Dr. Berelowitz is currently Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit at Pfizer, Inc., the world's largest research-based pharmaceutical company.

Dr. Berelowitz joined Pfizer in 1996, after a number of years in academia, as a Medical Director in the Diabetes Clinical Research team. Since then he has assumed positions of increasing responsibility until being appointed to his present role in 2009. Among his public activities, Dr. Berelowitz has served on the board of directors of the American Diabetes Association, the Clinical Initiatives Committee of the Endocrine Society, and has chaired the Task Force on Research of the New York State Council on Diabetes. He has also served on several editorial boards, including the Journal of Clinical Endocrinology and Metabolism and Endocrinology, Reviews in Endocrine and Metabolic Disorders and Clinical Diabetes. Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes and metabolic disorders.

"Dr. Michael Berelowitz joins our board and Oramed gains a renowned industry leader in the study of diabetes. His extensive experience should help us bring our insulin capsule ORMD-0801 through trials and to market. We are delighted to have him as part of our team," states Nadav Kidron, Oramed Chief Executive Officer.

"I have been closely following Oramed's progress and am impressed with the significant advances that the company has made in developing its novel oral insulin capsule, ORMD-0801," said Dr. Berelowitz. "I am very pleased to join Oramed's Board of Directors and look forward to working with the leadership team to enhance the development of therapeutic applications of the company's oral drug delivery technology and in the further maturation of ORMD-0801."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company Address

Oramed, Inc.

Tara Horn

Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, 91390, Israel

T U.S. 1-646-240-4193Israel +972-2-566-0001Fax +972-2-566-0004

Investor Relations

Emerging Markets Consulting, LLC.

Web Address:

Contact Us:
(321) 206-6682
126 S. Bumby Ave. Suite A
Orlando, FL 32803

Disclaimer: Emerging Markets Consulting, LLC (“EMC”) prepares and/or assists others in preparing and publishing oral and written information on selected companies (the “Profiled Companies”) and/or their securities (the “Securities”) in various contexts, including but not limited to corporate and business profiles, summaries, reports, and press releases (hereafter referred to as the “Corporate Information”) through various methods including but not limited to: (a) facsimile; (b) email; (c) mail and courier; (d) world wide web, including but not limited to EMC’s website at www.emergingmarketsllc.com; and (e) personal contact at trade shows, business luncheons, seminars and/or meetings. The Corporate Information may be disseminated to broker-dealers, members of the general public, and the financial community (collectively the “Recipients”) at the direction of the Profiled Companies and should be used by the Recipients for informational purposes only.

EMC and/or its principals, affiliates and representatives receive cash and/or compensation in the Securities in connection with preparation and dissemination of the Corporate Information. EMC did not pay cash consideration for the Securities that it holds (other than payments that may be made by EMC to the Profiled Companies for the exercise of warrants), and any of the Securities held by EMC were issued in exchange for EMC’s services. Because EMC is a Shareholder of the Profiled Companies, EMC may have a conflict of interest with the Recipients as well as the Profiled Companies. Independent of any compensation that EMC and/or its principals, affiliates, and representatives may receive, EMC and/or its principals, affiliates, and representatives may at any time purchase and/or sell the Securities, including simultaneous with the publication or distribution of the Corporate Information. The buying and selling of the Securities by EMC and/or its principals, affiliates, and representatives may negatively effect the price of the Securities or cause the price of the securities to increase or decrease or become unstable.

EMC does not express any opinions, recommendations or viewpoints regarding the Profiled Companies or the Securities, and has not conducted due diligence of any data or information contained in the Corporate Information. The Corporate Information is based solely upon data and information provided by the Profiled Companies and EMC does not endorse, independently verify, or assert the truthfulness, completeness, accuracy or reliability of the Corporate Information. EMC conducts no due diligence of any type of the Profiled Companies or the Securities. Recipients should not rely on the data or information contained in the Corporate Information in making an investment decision and should conduct their own research of the Profiled Companies. The Recipients should not assume that material changes have not occurred since the publication and/or dissemination of in the Corporate Information. Each of the Recipients should consult with his or her legal, accounting, tax and financial advisers regarding any investment in the Profiled Companies or the Securities.

EMC is not a registered investment advisor or registered securities broker dealer and no information contained within the Corporate Information should be construed as investment advice or as a solicitation to offer, purchase or sell the Securities. The Securities may be thinly traded and not listed on any national securities exchange and involve an extremely high degree of risk. Because the Securities are penny stocks, they are subject to the Securities and Exchange Commission's penny stock rules, and as such, any investment in the Securities involves a high degree of risk and it may be difficult for any investor or Shareholder to resell the Securities. An investment in the Securities could result in the loss of some or all of an investment.

Recipients should (with the assistance of their legal and financial advisors) review Securities and Exchange Commission (“SEC”) filings regarding the Profiled Companies that are SEC reporting issuers. These SEC filings are available for review at
www.sec.gov. Recipients should review investment guides that are available at the same SEC website and the National Association of Security Dealers website at www.nasd.com.

Statements contained in the Corporate Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified by the use of terminology such as “believes”, “expects”, “may”, “will”, or “should”, or “anticipates”. Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Corporate Information. The actual results of a Profiled Company’s operations, financial condition or other aspects of its business could differ materially from those discussed in the Corporate Information.

The issuance of the Securities to EMC may cause shareholders and/or investors of the Profiled Companies to experience immediate and substantial dilution of their holdings and/or investments in the Profiled Companies. Future securities issuances to EMC for services may also result in a reduction of (i) the book value or market price of the Profiled Companies’ securities, (ii) shareholder voting power; and (iii) each shareholder’s proportionate ownership of any Profiled Company.

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below:

Disclaimer EMC has a December 16, 2009 contract to provide Investor Relations services for Oramed Pharmaceuticals for a six month period. The company is to pay EMC 100,000 restricted shares of Stock and $5,000 monthly. EMC has been paid $35,000 and 100,000 restricted shares. View full disclaimer at http://app.streamsend.com/c/10935471/1788/SJDP5EQ/JTKY?redirect_to=http%3A%2F%2Fserver1.streamsend.com%2Fstreamsend%2Fclicktracker.php%3Fcd%3D5119%26amp%3Bld%3D2%26amp%3Bmd%3D209%26amp%3Bud%3Dabc90c6eee3041cdd572857428e5a03f%26amp%3Burl%3Dhttp%3A%2F%2Fwww.emergingmarketsllc.com%2Fdisclaimer.php